AstraZeneca says board will review Pfizer offer
LONDON (Reuters) - AstraZeneca's board will be reviewing a sweetened takeover offer from Pfizer but the company has no further comment at this stage, a spokeswoman for the British drugmaker said on Friday.
Earlier the U.S. drugmaker revealed it had raised its offer for the British group to 63 billion pounds ($106 billion).
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video